Savara reports third quarter 2021 financial results and provides business update

Austin, texas--(business wire)--savara inc. (nasdaq: svra), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending september 30, 2021 and provided a business update. “the team is focused and driving hard on advancing the pivotal phase 3 impala 2 trial,” said matt pauls, chair and chief executive officer, savara. “given that an increasing number of sites are actively screening and enrolling patients, and we c
SVRA Ratings Summary
SVRA Quant Ranking